摘要
目的评价运用18F-FDG PET/CT的方法监测同步和交替放化疗治疗晚期非小细胞型肺癌(NSCLC)的疗效。方法对同步和交替放化疗治疗晚期NSCLC的过程中,采用18F-FDG PET/CT的检测手段对患者用药方案进行调整和临床疗效评价。结果治疗结束后,同步放化疗组和交替放化疗组的SUVmax值、SUVmean值、MTV值均下降,但同步放化疗组的下降百分率比交替放化疗组的高,差异有统计学意义(P=0.032,0.021);同步放化疗组MTV值的下降百分率亦比交替放化疗组高,且差异有统计学意义(P=0.004);同步放化疗组的CR率、PR率、中位生存期、胃肠道反应率、骨髓抑制率均比交替放化疗组高,而局部复发率、远地转移率均较交替放化疗组低,P<0.05,差异有统计学意义。结论运用18F-FDG PET/CT的检测方法监测同步放化疗治疗NSCLC的效果优于交替放化疗的方案。
Objective To evaluate the effect of the two therapeutic regimen concurrent chemoradiotherapy and alternating chemoradio-therapy on the treatment of the non-small cell lung cancer（NSCLC） monitored by the [18F] fluorodeoxyglucosepositron emission tomography/computed tomography （18F-FDGPET/CT） assay. Methods Adjusted the medication and evaluate the treatment response by the way of 1SF-FDG PET/CT assay in every treatment cycle of NSCLC. Results The values of SUVmax, SUVmean, MTV were decreased in concurrent chemoradiotherapy and alternating chemoradiotherapy group. The percentage of reduction of SUVmax and SUVmean was higher in the concurrent chemoradiotherapy group than that in the alternating chemoradiotherapy group （P = 0.032, 0.021）, and the percentage of reduction of MTV was significantly high in concurrent chemoradio therapy group compared with the alternating chemoradiotherapy group （P = 0.004）. The median survival and the ratio of CR, PR, gastrointestinal reaction and bone marrow suppression were higher in concurrent chemoradiotherapy group than that in alternating chemoradiotherapy group （P 〈 0.05）, while the local recurrence rate and distant metastasis rate were lower in concurrent chemoradiotherapy group than that in alternating chemoradiotherapy group （P 〈0.05）. Conclusion The therapeutic regimen of concurrent radiotherapy chemotherapy is better than that of alter- nating radiotherapy chemotherapy under the monitor of 18F-FDGPET/CT assay.
出处
《中国现代医生》
2012年第8期7-9,共3页
China Modern Doctor
